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Regenerative dentistry represents an attractive multidisciplinary therapeutic 
approach that complements traditional restorative/surgery techniques and 
benefits from recent advances in stem cell biology, molecular biology, 
genomics and proteomics. Materials science is important in such advances 
to move regenerative dentistry from the laboratory to the clinic. The design 
of novel nanostructured materials such as biomimetic matrices and scaffolds 
for controlling cell fate and differentiation, and nanoparticles for diagnostics, 
imaging and targeted treatment is needed. The combination of 
nanotechnology, which allows the creation of sophisticated materials with 
exquisite fine structural detail, and stem cell biology turn out to be 
increasingly useful in regenerative medicine. The administration to patients 
of dynamic biological agents composed by stem cells, bioactive scaffolds 
and/or nanoparticles will certainly increase the regenerative impact of dental 
pathological tissues. This overview briefly describes some of the actual 
benefits and future possibilities of nanomaterials in the emerging field of 
stem cell-based regenerative dentistry. 
 
1. Pathology and natural regenerative potential of dental tissues 
 
Two of the hardest tissues of the body, the enamel and dentin, form as the 
outcome of sequential and reciprocal interactions between cells of the oral 
epithelium and the cranial neural crest-derived mesenchyme [1]. 
Mesenchymal cells give rise to the dental follicle and dental pulp, while the 
 3 
oral epithelium forms the ameloblasts. A part of the dental pulp cells 
differentiate into odontoblasts that produce dentin matrix, whilst ameloblasts 
form the enamel. When the mineralization of the tooth-crown is completed, 
the tooth-root starts to develop and subsequently the tooth erupts in the oral 
cavity. Once root development and cementum deposition have been 
accomplished the tooth anchors to the surrounding alveolar bone through 
the periodontal ligament (PDL), which contains extracellular matrix and a 
great variety of cells such as fibroblasts, epithelial rests of Malassez, 
endothelial cells.  
 
The mineralized dental tissues are vulnerable to various external harmful 
agents such as bacteria and acids, but also to traumatic injuries that 
jeopardize tooth integrity. Although the mitotic and secretory activities of 
dental pulp and periodontal cells are reduced in adult teeth, these biological 
processes can be reactivated in pathological conditions (e.g., periodontal 
and carious diseases) or following traumatic injury [2]. After a mild lesion 
such as early caries, surviving post-mitotic odontoblasts can produce new 
dentin through a process known as reactionary dentinogenesis. However, a 
severe dental injury leads to odontoblast apoptosis that activates dental pulp 
stem cells to differentiate into new odontoblasts, which are producing the 
reparative dentin [2]. Periodontal regeneration is a complex process that 
involves the interaction of several populations of cells that control the 
specific extracellular matrix components. Cell-occlusive barriers ranging 
from cellulose to synthetic absorbable materials, which restrict the 
repopulation of the periodontium from epithelial cells and favor growth of 
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PDL cells and cementoblasts, are commonly used for periodontium 
regeneration in dental clinics. These materials are often used in conjunction 
with biological factors to enhance the regeneration of the alveolar bone. 
Damaged enamel cannot be repaired naturally since ameloblasts are not 
present anymore in humans after tooth eruption. Thus, a common practice 
in dental clinics is to substitute the damaged enamel with biomaterials, 
ceramics and precious metals.  
 
It is evident that the natural regenerative capacity of dental tissues is often 
insufficient to entirely restore damaged teeth. In such cases, stem cell 
biology combined with tissue engineering technology could be useful for the 
development of innovative strategies for cell-based dental tissue 
regeneration [3, 4].  
 
2. Stem cell populations within dental and periodontal tissues 
 
Stem cells are undifferentiated cells characterized by their ability to self-
replicate throughout life and their capacity to differentiate into diverse 
specialized cell types [5]. Adult stem cells are found in various tissues of the 
human body from both epithelial and mesenchymal origin, including skin [6], 
adipose tissue [7], periosteum [8] and cartilage [9]. Due to their ability to 
give rise to every cell type in a given tissue, adult stem cells are responsible 
for tissue/organ homeostasis and regeneration.  
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Mesenchymal stem cells (MSCs) have been isolated from different locations 
within adult or postnatal dental tissues. Dental mesenchymal stem cells 
(DMSCs) have been isolated from the pulp of adult and deciduous teeth 
(DPSCs and SHEDs respectively) [10], apical part of dental papilla (SCAP) 
[11, 12], dental follicle (DFSCs) [13], and periodontal ligament (PDLSCs) 
[14, 15] (Figure 1).  All these dental stem cell populations express typical 
MSCs markers such as Stromal-derived factor 1 (STRO-1), Melanoma-
associated antigen (MUC-18) or Cd146, and Cd44 [16] but some of them 
also express other markers including Cd90, Cd73, Cd29 and Cd24 [11, 17]. 
However, the marker or combinations of markers that reliably recognize 
dental stem cells have not been established yet. Thus, DMSCs are often 
recognized by their ability to give rise to odontogenic [10, 16, 18-21], 
adipogenic [16, 22], chondrogenic [22], osteogenic [23], myogenic [24], and 
neurogenic [16, 25] lineages in vitro or to regenerate dental tissues in vivo 
[11, 17]. 
 
Since most of dental epithelial cells disappear shortly after tooth eruption, 
identifying epithelial stem cells (EpSCs) within adult dental tissues 
constitutes a major challenge. Putative EpSC populations have been 
isolated from third molars [26] and, most surprisingly, dental pulp [27]. 
However, to date, epithelial cell rests of Mallassez (ERM) located in the 
periodontal ligament (Figure 1), appear as the more promising source of 
EpSCs [28, 29]. 
 
 6 
Recently, pluripotent stem cells, named dental pulp pluripotent stem cells 
(DPPSCs) have been isolated from the dental pulp of third molars [30]. 
These cells show the ability to differentiate into tissues that derive from 
embryonic mesodermal, endodermal and ectodermal layers, suggesting 
their potential utility for the regeneration of both epithelial and mesenchymal 
dental tissues.  
 
3. Stem cell-based dental tissue regeneration  
 
Harmful agents (e.g., caries) damage firstly the hard tissues of the tooth and 
then reach the dental pulp. The affected dental pulp is usually amputated 
(pulpotomy) or extracted (pulpectomy) and substituted with an artificial 
material after disinfection of the pulp cavity [3]. Although the tooth is 
preserved in its normal position, it is not vital anymore and it cannot fulfill 
completely its role [3]. Thus, the regeneration of the dentin-pulp complex 
represents the ideal solution and this process requires the revascularization 
and reinnervation of the pulp, as well as the deposition of newly generated 
dentin. As previously mentioned, DPSCs have the ability to differentiate into 
odontoblasts, endothelial cells, and neurons among other cell types. In 
mice, transplantation of DPSCs can regenerate both pulp and dentin tissues 
in vivo after pulpotomy [31]. DPSCs and SCAPs isolated from human third 
molars, seeded on a poly-D,L-lactide/glycole scaffold, and transplanted into 
the empty root canal space of mouse teeth, were able to refill the empty 
space with a newly formed vascularized pulp [17, 32]. A continuous layer of 
mineralized tissue resembling dentin was deposited in the existing dental 
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walls of the canals [17, 32]. Although these results prove that DPSCs can 
regenerate the dental pulp, further studies are clearly required to investigate 
their potential clinical applications.  
 
Periodontitis is one of the most common infectious diseases in humans. 
Periodontitis is triggered by microorganisms that attach to the teeth, cause 
chronic inflammation and eventually destroy the periodontal tissues [3]. 
Studies in immunocompromized mice have shown that transplanted 
PDLSCs were able to regenerate the periodontium, thus indicating their 
huge potential for future cell-based therapies in dental clinic [3]. However, 
severe damage of the periodontal tissues often results in tooth loss, so it is 
still necessary to develop new strategies in order to potentially use entirely 
regenerated teeth in clinics. This could be achieved either by generating a 
tooth germ in vitro before implanting it in vivo, or by grafting dental stem 
cells in the oral cavity. In this last case, dental stem cells could be carried on 
tooth-shaped biomimetic scaffolds [3]. Using different scaffolds it has been 
possible to induce differentiation of PDLSCs and DPSCs into the various 
cell types composing the root and/or the periodontal tissues both in vitro and 
in vivo [33, 34]. Dental pulp, cementum and PDL have been obtained by 
transplanting subcutaneously human DPSCs that were placed into a natural 
scaffold composed of human dentin matrix [33]. Regarding regeneration of 
dental epithelium, it has been shown that ERM derived from porcine 
mandible can differentiate into ameloblasts after co-culture with dental pulp 
cells in vitro. These ameloblast-like cells were positive for Keratin 14 (K14) 
and amelogenin. Moreover, after transplantation of ERM cells combined 
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with primary dental pulp cells, an enamel-like tissue was produced in the 
implant. Histological analysis revealed that appropriate stages of 
amelogenesis from initiation to maturation were present in all implants. 
Thick enamel-dentin structures were clearly recognized, with ameloblast-like 
cells expressing K14 and amelogenin were found 8 weeks post-
transplantation [29]. 
 
Equally important for the development of stem cell-based therapies in 
dentistry is the use of signaling molecules. Several molecules involved in 
periodontal development are already in use in the clinical practice. Long 
time ago, it was shown that PDGF molecules were able to stimulate 
periodontal healing and regeneration [35, 36].  Since then, other molecules 
such as BMPs [37-39] and amelogenins [40] have been used for the 
stimulation of periodontal tissues regeneration.  
 
Current studies focus on the identification of the accurate population of cells, 
suitable signaling molecules, and desirable scaffold materials that will be 
used as carriers for specific cell types. 
 
4. Safety and efficacy issues of stem cell-based therapies in dentistry 
 
Stem cell-based therapies are both promising and challenging. The 
engraftment of exogenous therapeutic cells in patients must obey strict 
safety rules, exclude tumor formation, and avoid or minimize rejection [41, 
42]. The purity, biological activity, and quantity of the injected cells should 
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be optimized to ensure cell functionality. Cell functionality should be tested 
both in vitro and in vivo in various animal models. Defined strategies should 
also develop to monitor the behavior and fate of the engrafted cells before 
any clinical trial. There is a consensus that differentiated cells that are 
originated from stem cells and not undifferentiated stem cells should be 
used directly for transplantation in the clinics [42]. Even if stem cell injection 
or transplantation is successful in animal models, it is important to optimize 
and secure stem cell-based therapeutic strategies before clinical trials. 
 
An optimal engraftment strategy must avoid (or minimize) immune response 
in the host. Grafted or injected stem cells are recognized as foreign material 
by the immune system of the host, thus generating a cascade of events that 
results in the destruction and rejection of the transplanted cells. This 
process can compromise the immune status of the recipient. 
Immunosuppressive treatments that increase graft survival are not desired, 
since it has been shown that a correlation exists between the length of 
exposure to immunosuppressive drugs and the risk of malignancy after stem 
cell transplantation. Recent results have shown that mesenchymal stem 
cells from umbilical cord blood, dental pulp, periodontal ligament and bone 
marrow have immunosupressive properties in vitro [43-45]. Moreover, 
clonogenic nature of adult stem cells represents an advance over 
heterogeneous stem cells populations resulting in a more reproducible, 
potent immunosuppressive effect between patients [46]. Autologous cell-
based therapies are advantageous because there is a minimal risk of 
immunological rejection and disease transmission. However, the outcome of 
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all tissue engineering approaches using autologous stem cell transplantation 
is subjective to the patient since the patient is at the same time the source 
and the recipient of the cells that will be used for his/her own treatment. 
Factors related to the age, general health status of the patient, health 
condition of the dental pulp and periodontium at the moment of surgery, as 
well as the size and site of the injury may influence the efficacy of stem cell-
based dental treatments. The influence of these factors on the efficacy of 
cell preparations for cell-based dental treatments has not been investigated 
exhaustively.  
 
The generation of iPSCs by reprogramming somatic cells via a cocktail of 
transcription factors [47, 48] could be advantageous towards cell-based 
regenerative therapies. Somatic cells have been reprogrammed and turned 
into pluripotent cells by the overexpression of a cocktail of 4 transcription 
factors (Oct4, Sox2, c-Myc and Klf4) [47]. It has been recently shown that 
mouse iPSCs can give rise to neural crest-like cells that can be further 
differentiated into odontogenic mesenchymal cells [49]. iPSCs could be 
generated from somatic cells of the patient, who will be donor and recipient 
simultaneously, thus overcoming the problems of an allogeneic immune 
rejection [50]. Although tempting, this potential has not been proven, since 
there is no yet a clear understanding of the effects that the reprogrammed 
cells could have to the immune system [51]. For example, studies in animal 
models have shown immunoreactivity toward grafted iPSCs of the same 
genetic background [52]. Both adult dental stem cells and induced 
pluripotent stem cells (iPSCs) represent an attractive source of cells for 
 11 
regenerative dentistry. Nevertheless, there are still safety and 
immunogenicity issues that should be overcome before using them in clinics. 
 
Although promising advances have been made in dental stem cell isolation 
and expansion, it is still necessary to refine these procedures. It is 
noteworthy that stem cells from every individual patient should be 
considered as specific pools and be quality controlled accordingly. It is 
obvious that there is no yet an ideal and unique approach for cell-based 
repair of dental tissues. However, rapid progress in stem cell biology and 
biomaterial sciences might allow the development of new methods and 
protocols for personalized dental treatments. 
 
5. Nanomedicine: a giant leap forward disease diagnosis and treatment 
 
Nanomedicine represents a subfield of nanotechnology that uses particles in 
the size range 1-1,000 nm for the treatment, diagnosis, monitoring, and 
control of various diseases [53, 54]. Nanoparticles, which are similar in scale 
to biological macromolecules such as DNA and proteins [53], can be used 
for targeted therapy through DNA, protein and drug delivery, in vivo imaging, 
diagnostics, as well as for the creation of active scaffolds and implants [55-
57]. Nanoparticles can be composed of organic (e.g., lipids), inorganic 
materials (e.g., iron oxide, gold), or combinations of both types. Novel and 
improved nanostructured materials can be tailored by engineering their 
characteristics such as structure, stability, size, shape and surface 
properties in order to be selectively delivered to precise sites (target 
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regions) of the body [58]. This can be achieved through passive or active 
targeting mechanisms: passive targeting is enabled by the enhanced 
vasculature permeability during neo-angiogenesis of injured or pathological 
body sites, while active targeting benefits from the overexpression in the 
infectious or damaged areas of several cell surface molecules that can bind 
specifically to pre-coated nanoparticle ligands [58, 59]. Recently, a dual 
modular system that mimics the communication dependent recruitment of 
inflammatory cells to regions of disease has been developed to improve 
tissue target efficiency of nanoparticles [60]. Another more recent study has 
demonstrated the programming and assembly of DNA-based nanorobots 
that are able to carry molecular loads, transport chemical ingredients to 
target cells and stimulate their intracellular alterations [61].  
 
These sophisticated biomaterials are increasingly being incorporated into 
the stem cell biology field. The combination of stem cells with innovative 
nanotechnology products holds great promise for applications in the 
biomedical arena. Fundamental challenges include stem cell expansion in 
vitro without using feeder layers, enhancement of stem cells survival after 
transplantation and reproducible regulation of their fate in the body [55]. The 
development of nanomaterials could be helpful in detecting and 
manipulating stem cells that will be used for tissue repair in the clinic. 
Nanomaterials are being used to define precisely the stem cell 
microenvironment through the provision of morphogenetic gradients and cell 
adhesion molecules, to direct stem cell fates, and to provide a template for 
stem cells for the formation of new tissues and organs. Furthermore, 
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internalization of nanoparticles, previously labeled with chelated ions, small 
molecules, metals and nanocrystals, by stem cells enables their detection 
by imaging. The physical, chemicals and biological properties of 
nanomaterials can be exploited to influence proliferation, attachment, fate 
and differentiation of stem cells [62]. This multidisciplinary approach allowed 
scientists to create a fully synthetic organ for transplantation after soaking a 
porous polymer nanocomposite tracheobronchial replica in a solution of 
bone marrow stem cells [63]. Although these new developments are 
encouraging, long-term studies are necessary before exploitation of such 
synthetic nanosystems in the clinics. For example, it is important to verify 
the non-toxicity, exclude the tumorigenic potential [64] and adverse side 
effects on a systemic level of nanoparticles and study their interference with 
the self-renewal ability of stem cells. In addition, the pharmaceutical industry 
has been reticent to engage with the cell-based regenerative medicine 
industry probably because of the complex regulatory and ethical issues [65]. 
This leads to uncertainty regarding the cost and time that will be required to 
successfully gain market approval for the nanomedicine.  
 
5.1. Monitoring of stem cells after transplantation: magnetic 
nanoparticles and quantum dots 
 
Stem cell-based regenerative therapies necessitate thorough testing firstly 
in animals and finally in humans. For the evaluation of the therapeutic 
efficacy of the transplanted stem cells it is important to track their survival, 
migration, fate and regenerative impact in vivo. Transplanted stem cells can 
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be assessed for long-term periods using non-invasive imaging techniques 
[66, 67]. Stem cells can be tracked in vivo after their transplantation using 
different strategies: initial labeling of stem cells with fluorescent dyes or 
magnetic nanoparticles such as the superparamagnetic iron oxide (SPIO), 
and stem cell transfection with several reporter genes such as the LacZ and 
Green Fluorescence Protein (GFP) [68, 69]. The visualization of the labeled 
stem cells requires either simple or complex and sophisticated imaging 
systems such as the magnetic resonance imaging (MRI) [66, 70, 71], 
computed tomography (CT) imaging [72], positron emission tomography 
(PET) and single-photon emission computed tomography (SPECT) imaging 
[73]. SPIO nanoparticles (60-150 nm in diameter) are composed of 
biodegradable and recyclable iron and are coated with dextran or 
carboxydextran to prevent aggregation and ensure aqueous solubility [74, 
75]. Magnetic nanoparticles can attach to the stem cell surface, but are also 
capable to be internalized by phagocytosis or, more often, by endocytosis 
[76], a process that is often facilitated by the use of coating and membrane 
receptor-binding agents [69, 77]. Endocytosis of magnetic nanoparticles 
does not affect stem cells viability, growth, fate and differentiation [78].  
 
Quantum dots (QDs) are cadmium selenide semiconductor fluorescence-
emitting nanostructures (less than 10 nm in diameter) that are used for long-
term labeling of stem cells [79-81]. QDs present a number of advantages 
over conventional organic dyes (e.g., DiI) and fluorescence proteins (e.g., 
GFP): high brightness, superb photostability and a single excitation 
wavelength for multiple colors [82]. Due to their excellent optical properties, 
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the detection of QDs-labeled stem cells relies on imaging systems that are 
less sophisticated and complex than MRI. QDs have been used to monitor 
in real time the dynamics of various cell components [83]. Information 
concerning participation and clustering of multiple cell-surface molecules 
involved in stem cell migration and differentiation might be useful for the 
design of innovative scaffolds for homing stem cells before transplantation. 
QDs are also internalized by endocytosis, which is improved by the use of 
specific peptides such RGD, phospholipids, and cholera toxin [84-86]. A 
number of internalized QDs are transported via endosomes to the 
perinuclear region [87], while QDs that will not be used by the cells display 
an oxidative degradation [68] that could lead to mitochondria dysfunction 
and ultimately cell death [88]. It is possible that the composition and physical 
properties of QDs and magnetic nanoparticles lead to unique toxic 
responses [53, 85, 87]. To date there is no conclusive evidence of known 
human toxic responses that are exclusively caused by nanomaterials [53]. 
Furthermore, most of the studies demonstrated no interference of these 
nanoparticles in stem cell differentiation [84, 85]. However, variations in the 
composition, structure, size, and surface coating of nanoparticles might 
influence stem cell behavior and fate [88, 89].  
 
Magnetic nanoparticles and QDs may provide valuable information about 
stem cell migration, anchorage, fate and differentiation in the context of 
dental pathology (e.g., periodontitis, pulpitis, traumatic injury) and repair [3, 
5, 90]. For example, internalized nanoparticles would allow monitoring 
kinetics and fate of the labeled stem cells that were injected into the 
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periodontal space or pulp chamber following dental injury (Figure 2). These 
approaches are necessary to evaluate the therapeutic effects of stem cells 
when exposed to a specific microenvironment before their application in 
dental clinics.  
 
5.2. Targeting therapy: gene, protein and drug intracellular delivery 
 
One of the most attractive concepts in manipulating the fate of stem cells, 
directing thus their differentiation into specific cell populations, is the use of 
nanomaterials for intracellular gene delivery (e.g., RNAi, DNA) [91, 92]. 
Generally, viral (e.g., adenoviruses, lentiviruses, retroviruses) and non-viral 
vectors (e.g., lipids, polymers) can be used for cellular transfection and/or 
nucleofection, thus offering durable gene expression within stem cells [93-
96]. Non-viral carriers have a number of advantages over viral vectors, since 
they exhibit low-risk immunogenicity and insertional mutagenesis, 
controllable toxicity, and great gene-carrying capacity [95]. Many efforts for 
the improvement of non-viral vectors are focused on cationic polymers that 
interact with negatively charged DNA or RNAi. Polymers, including poly(L-
lysine)-palmitic acid, poly(L-lysine), and polyethylenimine, condense the 
genetic material into particles of 200-300 nm in diameter, protect them from 
enzymes, and facilitate cellular entrance [94, 97]. These complexes of 
polymers with genetic material (called “polyplexes”) have a transfection 
efficiency that is equivalent to the adenoviral vectors [97]. 
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Nanoparticles, carbon nanotubes and silicon nanowire arrays have also 
been used for gene delivery [98, 99]. The apatite particles coated with E-
cadherin and fibronectin, ensure high gene delivery capacity in stem cells 
[100]. 
 
Polymeric biodegradable nanoparticles of 100-300 nm in diameter could 
also serve as platforms to incorporate and deliver proteins and chemicals 
within stem cells. It has been shown that after internalization these 
nanoparticles accumulate in the perinuclear region and have a minimal 
effect on the viability and proliferation of stem cells, but a high impact on 
their differentiation [68]. 
 
The cytotoxicity of “polyplexes”, nanoparticles, and nanotubes has been 
evaluated in stem cells and the results showed that in general the toxicity 
correlates with the chemistry, concentration, size, shape and coating of the 
nanomaterials [97, 98].  
 
5.3. Nanobiomimetics: design of bioactive scaffolds and artificial stem 
cell niches 
 
The behavior of stem cells is tightly controlled by a specialized 
microenvironment called the “stem cell niche” [5]. Thus, this 
microenvironment regulates the survival, proliferation and differentiation of 
stem cells.  
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Injection of stem cells into the injured or pathological tissue limits their 
spreading and, in addition, does not ensure their good engraftment [101]. 
Injected cells could die due to the absence of trophic factors, oxygen, or lack 
of a suitable extracellular matrix (ECM) for their adhesion. This can be 
avoided by placing stem cells in biocompatible and biodegradable nanofiber 
scaffolds that recreate temporary the fibrous three-dimensional (3D) network 
of ECM and mimic the structural aspects of the stem cell niche. Hence, stem 
cells are anchored to the nanofibers of the scaffolds that behave as artificial 
stem cell niches, and then transplanted to the lesion site. This will improve 
stem cell survival, migration and differentiation potentials, and finally their 
3D organization [101]. Stem cells cultured on nanofiber scaffolds exhibit 
high viability and lower mobility, and differ in morphology when compared to 
cells cultured on conventional substrates (e.g., polystyrene) [102, 103]. 
Nanofibers with controlled diameter (e.g., 300-1,000 nm) are composed by 
either natural polymers, such as collagen and silk, or synthetic polymers 
including poly(lactic acid) and poly(amide) [102, 104, 105]. The 3D 
organization, surface and chemistry of these scaffolds result in stem cell 
self-renewal, migration, and differentiation. Nanofiber scaffolds have high 
porosity and specific surface that offer an ideal environment for stem cell 
homing.  
 
Identifying the appropriate stem cell populations and providing the suitable 
microenvironment that allows them to repair or regenerate an injured tissue 
is the key for a successful cell-based therapy. Nanotechnology can be used 
to create artificial microenvironments that will direct stem cells or progenitor 
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cells towards a precise fate and function. A big challenge is to engineer 
materials that resemble the structural complexity of stem cell niches, which 
represent specific anatomic locations homing stem cells and prevented 
them from exiting the mitotic cycle [106]. ECM molecules such as collagen, 
fibronectin, laminin, and proteoglycans represent the non-cellular 
components of the niches and are important for the creation of a particular 
microenvironment (e.g., tooth, bone, heart). ECM provides nanoscale 
structures such as the 15-300 nm in diameter collagen fibrils that allow cell 
adhesion (via integrins) and immobilization of signaling molecules, thus 
influencing the fate and behavior (i.e., proliferation, migration, differentiation) 
of stem cells [107]. The concentration, size, spacing, surface chemistry and 
shape (e.g., ridges, grooves, pores, pits) of the artificial nanostructures (e.g., 
nanotubes, nanolines) are important parameters for the development of cell 
adhesion sites that monitor stem cell behavior [108-110]. For example, it 
has been shown that surface irregularity (e.g., nanoline grating) and diverse 
surface chemistries (e.g., silica, poly[methyl methacrylate]) are capable to 
enhance adhesion, alignment, growth, and differentiation of stem cells [108, 
109].  
 
In vivo transplantation of stem cells anchored to nanofiber-based scaffolds 
is a technique successfully used in regenerative medicine [111, 112]. 
Transplanted biodegradable scaffolds act as temporary niches that guide, 
by controlling stem cell behavior, the formation of a new specific ECM for 
tissue repair. The design of tissue-specific artificial niches offers new 
perspectives to stem cell-based applications in dentistry for the treatment of 
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peculiar anatomic sites (e.g., alveolar bone, dentin-pulp complex, enamel, 
periodontium). Furthermore, nanomaterials could be successfully used for 
the generation of new nanotextured “osteogenic coating” dental implants 
that may lead to direct bone-material contact and also bone healing in those 
cases in which bone is compromised. The variety of adult stem cell 
populations within dental tissues indicates that their differentiation potential 
and response to nanoscale materials may be different. However, there are 
not yet methodical comparative studies that will allow the assessment of 
nanomaterials on the various dental stem cell lines. The lack of this crucial 





There is no doubt that nanotechnology offers enormous benefits and a 
plethora of exciting perspectives to cell-based regenerative medicines. 
Recent advances in nanoscale materials increase the potential to control 
stem cell fate, improve DNA and drug delivery, modulate the immune 
response to implanted cells, and create advanced scaffolds for treatment of 
various diseases. Nanomaterials and cell-based products must be regulated 
and manufactured at a low cost scale to ensure their successful application 
in clinics. Dentists could benefit from the use of nanoparticles to label stem 
cells, which after being placed on scaffolds could be further implanted into 
damaged dental tissues in order to regenerate them (Figure 2). The 
application of nanotechnology for dental purposes (nanodentistry) holds 
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great promise as a type of personalized medicine for the management of 




Dental clinics could benefit in the near future from the combinatorial use of 
stem cells and nanostructures (e.g., creation of specific scaffolds). These 
devices that will contain cells could be implanted into damaged dental sites 
in order to regenerate them. However, there are serious issues concerning 
standardization of techniques, nanoparticles and stem cells that have to be 




1. Pathology and natural regenerative potential of dental tissues 
The mineralized dental tissues are vulnerable to various external harmful 
agents such as bacteria and acids, but also to traumatic injuries that 
jeopardize tooth integrity. The natural regenerative capacity of dental tissues 
is often insufficient to entirely restore damaged teeth.  
 
2. Stem cell populations within dental and periodontal tissues 
Dental mesenchymal stem cells (DMSCs) have been isolated from the pulp 
of adult and deciduous teeth (DPSCs and SHEDs respectively), apical part 
of dental papilla (SCAP), dental follicle (DFSCs), and periodontal ligament 
(PDLSCs).  
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Putative epithelial stem cell populations (EpSCs) have been isolated from 
dental pulp. However, epithelial cell rests of Mallassez (ERM) located in the 
periodontal ligament, appear as the more promising source of EpSCs. 
 
3. Stem cell-based dental tissue regeneration 
Studies in animals have shown that transplanted dental mesenchymal stem 
cells (DMSCs) were able to regenerate the periodontium and dental pulp in 
vivo thus indicating their huge potential for future cell-based therapies in 
dental clinics. 
 
4. Safety and efficacy issues of stem cell-based therapies in dentistry 
There are still safety and efficacy issues that need to be solved before the 
application of stem cell-based therapies in clinics. Immunogeneicity of the 
transplanted cells is one example. The potential use of iPSCs in 
regenerative dentistry is discussed. 
 
5. Nanomedicine: a giant leap forward disease diagnosis and treatment 
Nanomedicine represents a subfield of nanotechnology that uses particles in 
the size range 1-1,000 nm for the treatment, diagnosis, monitoring, and 
control of various diseases. Different sophisticated biomaterials are 
increasingly being incorporated into the stem cell biology field. 
 
5.1. Monitoring of stem cells after transplantation: magnetic nanoparticles 
and quantum dots 
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For the evaluation of the therapeutic efficacy of the transplanted stem cells it 
is important to track their survival, migration, fate and regenerative impact in 
vivo. Stem cells can be tracked in vivo after their transplantation using 
different types of nanoparticles such as superparamagnetic iron oxide 
(SPIO) or quantum dots (QD). 
 
5.2. Targeting therapy: gene, protein and drug intracellular delivery 
Polyplexes, nanoparticles, carbon nanotubes and silicon nanowire arrays 
can be used for gene delivery to stem cells before they transplanting them in 
vivo. 
 
5.3. Nanobiomimetics: design of bioactive scaffolds and artificial stem cell 
niches 
Biocompatible and biodegradable nanofiber scaffolds constitute artificial 
stem cell niches that influence the survival, self-renewal and differentiation 
of stem cells. 
 
Conclusion 
The use of nanotechnology for dental purposes (nanodentistry) holds great 
promise as a type of personalized medicine for the management of target-
specific treatment and imaging of dental tissues. However, there are still 
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Figure 1. Schematic representation showing the various dental stem 
populations within an adult human tooth. Abbreviations: DPSCs, dental pulp 
stem cells; DPPSCs, dental pulp pluripotent stem cells; ERM, epithelial cell 
rests of Mallassez; PDL, periodontal ligament; PDLSCs, periodontal 
ligament stem cells; SCAP, stem cells from the apical papilla; SHED, stem 





Figure 2. Nanotechnology in regenerative dentistry. Dental stem cells 
(DSCs) can be labeled with nanoparticles before placing them into 
biomimetic scaffolds (A). Afterwards, those scaffolds that contain labeled 
DSCs could be transplanted to repair dental damaged tissues. Tooth crown, 
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